Online inquiry

IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11513MR)

This product GTTS-WQ11513MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FGFR3 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000142.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2261
UniProt ID P22607
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11513MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11563MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MG-A271
GTTS-WQ786MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Ab-2
GTTS-WQ8411MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HSP90mab
GTTS-WQ822MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ5335MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ3193MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ10546MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ1600MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-536
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW